Abdera Therapeutics
Namrata Menon is an experienced Associate Scientist currently working at Abdera Therapeutics since December 2022, with prior roles at Amgen and Biogen, where Namrata contributed to bioanalytical assay development and automation for gene therapy programs. Namrata has a solid background in drug discovery, having performed high-throughput screening and developed biochemical assays at EMD Serono, Inc. Additionally, Namrata's experience includes research assistance roles at Northeastern University and the University of Toronto, focusing on cell line maintenance, microfluidic device fabrication, and metabolite analysis. Namrata holds a Master of Science in Biotechnology from Northeastern University and a Bachelor of Science in Cell/Cellular and Molecular Biology from the University of Toronto.
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.